Rolle des Rezeptors für Hyaluronsäure-vermittelte Motilität RHAMM/CD168 bei der Proliferation myeloischer Blasten

Abstract

RHAMM, the receptor for hyaluronic acid mediated motility (CD168) was identified as leukemia associated and tumor associated antigen. In normal tissues RHAMM is not represented significantly. This declares RHAMM to an interesting target in therapy of myeloid neoplasms. The cell line K562 was in the focus of the studies. Nucleofection of small interfering ribonucleic acid (siRNA) against RHAMM led to an effective inhibition of the expression of RHAMM. Using realtime PCR, a reduction to 30 % of the expression after 72 h could be detected. At the same time analyses about growth and vitality of cells after nucleofection with siRNA showed an inhibition of cell growth. Summary: Nucleofection with siRNA is an effective method to reduce gene activity. Due to the biological characteristics, the effect is not permanent.